title: Increased risk of renal stones in patients treated with atazanavir.
authors.forename: Pierre
authors.initials: P
authors.lastname: Tattevin
authors.forename: Matthieu
authors.initials: M
authors.lastname: Revest
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Chapplain
authors.forename: Maja
authors.initials: M
authors.lastname: Ratajczak-Enselme
authors.forename: Cédric
authors.initials: C
authors.lastname: Arvieux
authors.forename: Christian
authors.initials: C
authors.lastname: Michelet
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D007669:Kidney Calculi / Q000139:chemically induced*; D008297:Male; D009842:Oligopeptides / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D019438:Ritonavir / Q000009:adverse effects*
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D019438:Ritonavir